Last reviewed · How we verify

Precocious puberty — Treatment Landscape & Competitive Intelligence

Precocious puberty (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Precocious puberty, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Synarel NAFARELIN Pfizer Gonadotropin Releasing Hormone Receptor Agonist Gonadotropin-releasing hormone receptor 1990-01-01
Lupron leuprorelin Accord Healthcare S.L.U. Gonadotropin Releasing Hormone Receptor Agonist GnRH receptors 1985-01-01
Lupron leuprolide Accord Healthcare S.L.U. Gonadotropin Releasing Hormone Receptor Agonist Gonadotropin-releasing hormone receptor 1985-01-01
Leuprolide Acetate leuprolide-acetate Pfizer leuprorelin Gonadotropin-releasing hormone receptor 1985-01-01
Eligard Eligard Astellas Pharma Europe Ltd. Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Accord Healthcare S.L.U. · 2 drugs in Precocious puberty
  2. Pfizer · 2 drugs in Precocious puberty
  3. · 1 drug in Precocious puberty
  4. Astellas Pharma Europe Ltd. · 1 drug in Precocious puberty

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Precocious puberty:

Cite this brief

Drug Landscape (2026). Precocious puberty — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/precocious-puberty. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing